ROS generated after the formation of ceramide or after an increase in energy metabolism induced by several receptor-interacting protein kinases (RIPs), either in the mitochondrial ETC and/or by NOXs, have been reported to enhance necroptosis 123,124,125
dosing protocols are derived from anecdotal and animal research rather than validated human data Sold strictly as a research chemical, so quality, sterility, and purity vary by vendor Requires reconstitution and subcutaneous injection, which some users find inconvenient compared to oral or topical options Side Effects: Commonly reported effects include injection-site redness or irritation, mild headache, fatigue, and lightheadedness shortly after dosing
IGF-1 Long R Class: Recombinant IGF-1 analog
Tesamorelin similarly does not hold a UK marketing authorisation
Cisplatin in cancer therapy: Molecular mechanisms of action